Feature | March 09, 2015

Study finds PET/MR image quality, diagnostic certainty higher than PET/CT

SNMMI, PET/MRI, PET/CT, foot pain, diagnosis, nuclear imaging

March 9, 2015 — A single scan could diagnose the cause of foot pain better and with less radiation exposure to the patient than other methods, according to a study in the March 2015 issue of The Journal of Nuclear Medicine. Imaging with 18F-fluoride positron emission tomography/magnetic resonance imaging (PET/MR), compared to 18F-fluoride positron emission tomography/computed topography (PET/CT), provides more diagnostic information with higher diagnostic certainty.

Foot pain is a common problem in the daily routine of any orthopedic surgeon. It can be a clinical symptom of many different issues, from stress fractures to tumors. Multiple imaging modalities are available to help diagnose specific types of foot pain, but no one modality is useful for effectively diagnosing a wide range of causes. Imaging with 18F-fluoride PET is a highly sensitive tool but has low specificity for detection of metabolically active benign bone disease, while MR imaging provides excellent soft-tissue contrast and high resolution, which helps in specifying a diagnosis. Thus, combined, PET/MR can offer an important tool for the sensitive diagnosis of foot pathologies.

In “Evaluation of 18F-Fluoride PET/MR and PET/CT in Patients with Foot Pain of Unclear Cause,” researchers compared the quality and diagnostic performance of 18F-fluoride PET/MR to those of 18F-fluoride PET/CT in 22 patients for whom the specific diagnosis was inconclusive after clinical examination and radiography. The results of overall image quality showed that PET/MR was significantly superior to PET/CT, with an overall excellent image quality score of 3.0/3 points in all PET/MR datasets, while PET/CT achieved 2.3 out of 3 possible points.

“In our study, 18F-fluoride PET/MR provided more diagnostic information at a higher diagnostic certainty compared to 18F-fluoride PET/CT in patients with foot pain of unclear cause,” stated Isabel Rauscher, corresponding author of the study. “Besides information on bone metabolism, it provides additional diagnostic-relevant findings from soft-tissue and bone marrow pathology (e.g., bone marrow edema, ganglion cysts or tenosynovitis) compared to PET/CT.” Also, since MR involves no radiation and the scan allows a longer PET acquisition time, the patient’s exposure is lower than with CT.

For more information: www.snmmi.org


Related Content

News | Clinical Trials

June 7, 2023 — The U.S. Food and Drug Administration (FDA) has announced the availability of a draft guidance with ...

Time June 07, 2023
arrow
News | Breast Imaging

May 25, 2023 — GE HealthCare, a leader in breast cancer care technology and diagnostics, has today announced that NCCN ...

Time May 25, 2023
arrow
News | Radiation Oncology

May 16, 2023 — The American Society for Radiation Oncology (ASTRO) today expressed its strong support for President ...

Time May 16, 2023
arrow
News | Contrast Media

May 16, 2023 — Bracco Imaging, an innovative world leader delivering end-to-end products and solutions through a ...

Time May 16, 2023
arrow
News | Contrast Media

May 15, 2023 — Guerbet, a global leader in medical imaging with more than 30 years of experience in MRI, announced that ...

Time May 15, 2023
arrow
News | PET Imaging

May 12, 2023 — A newly published meta-analysis indicates that amino acid PET can accurately differentiate recurrent or ...

Time May 12, 2023
arrow
News | Artificial Intelligence

May 8, 2023 — Artificial intelligence and machine learning (AI/ML) technologies are constantly finding new applications ...

Time May 08, 2023
arrow
News | Mammography

May 5, 2023 — The American College of Radiology (ACR), Breast Cancer Research Foundation (BCRF) and GE HealthCare ...

Time May 05, 2023
arrow
News | Computed Tomography (CT)

May 5, 2023 — According to an accepted manuscript published in ARRS’ own American Journal of Roentgenology (AJR), a high ...

Time May 05, 2023
arrow
News | Prostate Cancer

May 2, 2023 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of ...

Time May 02, 2023
arrow
Subscribe Now